Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.69 |
| ▸ | RXRA | P19793 | 2/20 | 0.67 |
| ▸ | RXRB | P28702 | 2/20 | 0.67 |
| ▸ | RXRG | P48443 | 2/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 3/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902027 | 0.88 | RXRA (0.68) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL1495294 | 0.87 | CTSV (0.60) | MAOBNR4A2MAOAMRGPRX4MEN1 | |
| SCHEMBL30467426 | 0.87 | CTSV (0.60) | MAOBNR4A2MAOAMRGPRX4MEN1 | |
| SCHEMBL1557204 | 0.85 | RXRA (0.65) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL2908969 | 0.85 | NPC1 (0.53) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL2910612 | 0.82 | RXRA (0.64) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL31591504 | 0.81 | MAOB (0.64) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL29784197 | 0.80 | RXRA (1.00) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL6522344 | 0.80 | RXRA (1.00) | MAOBRXRARXRBRXRGNR4A2 | |
| SCHEMBL12998983 | 0.80 | NR4A2 (0.65) | MAOBNR4A2MAOAMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| EP-2220029-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305166-A1 | NOVEL COMPOUNDS | F12, C1R, RPS4X | MAOB 2551/4885RXRA 334/4885RXRB 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.